|
1
|
Altekruse SF, Kosary CL, Krapcho M, et al:
SEER Cancer Statistics Review, 1975–2007. Bethesda,MD: National
Cancer Institute; 2010, Available at http://seer.cancer.gov/csr/1975_2007/.
|
|
2
|
Pagano L, Mele L, Casorelli I, et al:
Acute lymphoblastic leukemia in the elderly. A twelve-year
retrospective, single center study. Haematologica. 85:1327–1329.
2000.PubMed/NCBI
|
|
3
|
Leith CP, Kopecky KJ, Godwin J, et al:
Acute myeloid leukemia in the elderly: assessment of multidrug
resistance (MDR1) and cytogenetics distinguishes biologic subgroups
with remarkably distinct responses to standard chemotherapy. A
Southwest Oncology Group study. Blood. 89:3323–3329. 1997.
|
|
4
|
Hiddemann W, Kern W, Schoch C, et al:
Management of acute myeloid leukemia in elderly patients. J Clin
Oncol. 17:3569–3576. 1999.PubMed/NCBI
|
|
5
|
Wahlin A, Markevärn B, Golovleva I and
Nilsson M: Prognostic significance of risk group stratification in
elderly patients with acute myeloid leukaemia. Br J Haematol.
115:25–33. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Gajewski JL, Ho WG, Nimer SD, et al:
Efficacy of intensive chemotherapy for acute myelogenous leukemia
associated with preleukemic syndrome. J Clin Oncol. 7:1637–1645.
1989.PubMed/NCBI
|
|
7
|
Pedersen-Bjergaard J, Ersbøll J, Sørensen
HM, et al: Risk of acute nonlymphocytic leukemia and preleukemia in
patients treated with cyclophosphamide for non-Hodgkin’s lymphomas:
comparison with results obtained in patients treated for Hodgkin’s
disease and ovarian carcinoma with other alkylating agents. Ann
Intern Med. 103:195–200. 1985.PubMed/NCBI
|
|
8
|
Kantarjian H, O’brien S, Cortes J, et al:
Results of intensive chemotherapy in 998 patients age 65 years or
older with acute myeloid leukemia or high-risk myelodysplastic
syndrome. Cancer. 106:1090–1098. 2006.PubMed/NCBI
|
|
9
|
Lin J, Zhu HL, Lu XC, et al: Clinical
analysis of 12 acute leukemia patients aged over 80 years. Zhongguo
Shi Yan Xue Ye Xue Za Zhi. 19:139–142. 2011.(In Chinese).
|
|
10
|
Bross PF, Beitz J, Chen G, et al: Approval
summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia.
Clin Cancer Res. 7:1490–1496. 2001.PubMed/NCBI
|
|
11
|
Kindler T, Breitenbuecher F, Marx A, et
al: Efficacy and safety of imatinib in adult patients with
c-kit-positive acute myeloid leukemia. Blood. 103:3644–3654. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Silverman LR, Demakos EP, Peterson BL, et
al: Randomized controlled trial of azacitidine in patients with the
myelodysplastic syndrome: a study of the cancer and leukemia group
B. J Clin Oncol. 20:2429–2440. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lübbert M: DNA methylation inhibitors in
the treatment of leukemias, myelodysplastic syndromes and
hemoglobinopathies: clinical results and possible mechanisms of
action. Curr Top Microbiol Immunol. 249:135–164. 2000.
|
|
14
|
Rüter B, Wijermans PW and Lübbert M: DNA
methylation as a therapeutic target in hematologic disorders:
recent results in older patients with myelodysplasia and acute
myeloid leukemia. Int J Hematol. 80:128–135. 2004.PubMed/NCBI
|
|
15
|
Yu C, Rahmani M, Dent P and Grant S: The
hierarchical relationship between MAPK signaling and ROS generation
in human leukemia cells undergoing apoptosis in response to the
proteasome inhibitor Bortezomib. Exp Cell Res. 295:555–566. 2004.
View Article : Google Scholar
|
|
16
|
Fiedler W, Mesters R, Tinnefeld H, et al:
A phase 2 clinical study of SU5416 in patients with refractory
acute myeloid leukemia. Blood. 102:2763–2767. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Stirewalt DL and Radich JP: The role of
FLT3 in haematopoietic malignancies. Nat Rev Cancer. 3:650–665.
2003. View
Article : Google Scholar : PubMed/NCBI
|
|
18
|
Marcucci G, Byrd JC, Dai G, et al: Phase 1
and pharmacodynamic studies of G3139, a Bcl-2 antisense
oligonucleotide, in combination with chemotherapy in refractory or
relapsed acute leukemia. Blood. 101:425–432. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zagonel V, Lo Re G, Marotta G, et al:
5-Aza-2′-deoxycytidine (decitabine) is an effective agent for the
treatment of advanced myelodysplastic syndromes (MDS). Proc Am Soc
Clin Oncol. 11:2261992.(abstr).
|
|
20
|
Pinto A and Zagonel V:
5-Aza-2′deoxycytidine (decitabine) and 5-azacytidine in the
treatment of acute myeloid leukemias and myelodysplastic syndromes:
past, present, and future trends. Leukemia. 7(Suppl 1): 51–60.
1993.
|
|
21
|
Wijermans PW, Rüter B, Baer MR, et al:
Efficacy of decitabine in the treatment of patients with chronic
myelomonocytic leukemia (CMML). Leuk Res. 32:587–591. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Issa JP, Gharibyan V, Cortes J, et al:
Phase II study of low-dose decitabine in patients with chronic
myelogenous leukemia resistant to imatinib mesylate. J Clin Oncol.
23:3948–3956. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Claus R and Lübbert M: Epigenetic targets
in hematopoietic malignancies. Oncogene. 22:6489–6496. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Cashen AF, Schiller GJ, O’Donnell MR and
DiPersio JF: Multicenter, phase II study of decitabine for the
first-line treatment of older patients with acute myeloid leukemia.
J Clin Oncol. 28:556–561. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Blum W, Garzon R, Klisovic RB, et al:
Clinical response and miR-29b predictive significance in older AML
patients treated with a 10-day schedule of decitabine. Proc Natl
Acad Sci USA. 107:7473–7478. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lübbert M, Rüter B, Claus R, et al: A
multicenter phase II trial of decitabine as first-line treatment
for older AML patients with acute myeloid leukemia judged unfit for
induction chemotherapy. Haematologica. 97:393–401. 2012.PubMed/NCBI
|
|
27
|
Garcia-Manero G, Kantarjian HM,
Sanchez-Gonzalez B, et al: Phase 1/2 study of the combination of
5-aza-2′-deoxycytidine with valproic acid in patients with
leukemia. Blood. 108:3271–3279. 2006.PubMed/NCBI
|
|
28
|
DeLima M, Ghaddar H, Pierce S and Estey E:
Treatment of newly diagnosed acute myelogenous leukaemia in
patients aged 80 years and above. Br J Haematol. 93:89–95.
1996.PubMed/NCBI
|
|
29
|
Latagliata R, Alimena G, Carmosino I, et
al: Conservative treatment for patients over 80 years with acute
myelogenous leukemia. Am J Hematol. 71:256–259. 2002.PubMed/NCBI
|
